ARDS is a life-threatening condition in which the efficiency of the lungs is severely reduced. It is caused by damage to the capillary wall either from illness or a physical injury, such as major trauma.
The researchers investigated whether stem cells can affect the stimulation of the macrophages and promote the state in which they will suppress the inflammation. The results showed that treatment with stem cells led to significant reductions in lung injury, inflammation and improved bacterial clearance.
Dr Anna Krasnodembskaya, lead author of the study from the Queens University Belfast, said: “The findings highlight the advantages of stem cell treatment, as they can actively respond to the local micro-environment and exert multiple beneficial effects. We believe that clinical trials are now needed to test whether this can be an effective treatment for people suffering from ARDS.”
To read the article in more detail click here.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.